MSD eyeing Seagen acquisition, media reports

US-based biotech firm Seagen has benefitted on the stock exchange from rumors that pharmaceutical firm MSD was looking to buy.

Photo: MSD / PR

Pharmaceutical firm MSD is reported interested in buying US-based biotech firm Seagen, anonymous sources have told media Dow Jones News.

Following the rumors, Seagen shares increased by 16.9% to USD 171.6 on the stock exchange.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs